Handok-Aventis Pharma launches anti-rheumatic drug "Arava"

Handok-Aventis Pharma has newly launched Arava (leflunomide), a new disease-modifying anti-rheumatic drug (DMARD) that reduces inflammation and slows disease progression of rheumatoid arthritis (RA).

Arava is indicated in adults for the treatment of active rheumatoid arthritis to retard structural damage as evidenced by its specific mode of action to modulate the function of T-lymphocyte, a...